Asthma: Understanding Airway Inflammation, Diagnosis, Treatment and Prevention

 

Introduction

Asthma is a common chronic respiratory disease characterized by variable respiratory symptoms and variable expiratory airflow limitation. It affects people of all ages but is particularly common in children. The disease results from a complex interaction between airway inflammation, bronchial hyperresponsiveness, airway smooth-muscle contraction, mucus production, and structural changes within the airway wall. Because these processes can fluctuate over time, a person with asthma may feel completely well at one moment and develop significant breathing difficulty at another.

The characteristic symptoms of asthma include wheezing, shortness of breath, chest tightness, and cough. These symptoms may vary in intensity and frequency and are often triggered or worsened by viral respiratory infections, allergens, exercise, cold air, smoke, air pollution, occupational exposures, and other irritants. Symptoms may be particularly troublesome at night or in the early morning.

Asthma is not simply a disease of bronchospasm. Although contraction of airway smooth muscle is responsible for much of the acute airflow obstruction, persistent airway inflammation plays a central role in the disease. Modern management therefore focuses not only on relieving symptoms but also on treating the underlying airway inflammation and reducing the risk of future exacerbations.

Asthma is also a heterogeneous disease. Different patients can have different patterns of symptoms, triggers, inflammatory mechanisms, age of onset, associated allergic conditions, and responses to treatment. Some patients have predominantly allergic disease, while others may have non-allergic asthma, exercise-related symptoms, occupational asthma, or severe disease requiring specialized treatment.

The global burden of asthma remains substantial. The World Health Organization estimated that asthma affected approximately 363 million people in 2023 and was responsible for approximately 442,000 deaths. Underdiagnosis and undertreatment remain important problems, particularly in low- and middle-income countries.

Current international recommendations emphasize objective confirmation of the diagnosis whenever possible, assessment of symptom control and future risk, individualized treatment, correct inhaler technique, adherence to prescribed therapy, management of comorbidities, and an individualized action plan for worsening symptoms. The Global Initiative for Asthma (GINA) continues to update its recommendations as new evidence becomes available; its 2026 materials include updated guidance for asthma management and severe asthma.

Definition of Asthma

Asthma is a heterogeneous chronic respiratory disease usually characterized by chronic airway inflammation and a history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation.

This definition contains several important concepts. First, asthma is heterogeneous, meaning that it does not represent a single identical disease process in every patient. Second, airway inflammation is an important underlying feature, although the type and degree of inflammation may differ. Third, symptoms vary over time. Fourth, objective evidence of variable expiratory airflow supports the diagnosis.

The variability of airflow obstruction is one of the most important distinguishing characteristics of asthma. Airway narrowing can develop because of contraction of bronchial smooth muscle, thickening of the airway wall, inflammatory swelling, and excessive mucus. In many patients, this obstruction improves spontaneously or after treatment with bronchodilator medication.

Asthma should therefore not be diagnosed solely because a patient reports wheezing or because a patient improves after receiving a bronchodilator. Many other diseases can produce similar symptoms. Whenever possible, the clinical history should be combined with objective lung-function testing.

Epidemiology and Global Burden

Asthma occurs worldwide and affects both children and adults. It is among the most important chronic respiratory diseases and is the most common chronic disease of childhood. Its prevalence varies substantially between populations because genetic susceptibility, environmental exposures, urbanization, socioeconomic conditions, healthcare access, and diagnostic practices differ between regions.

The disease can impose a significant burden on individuals, families, healthcare systems, schools, and workplaces. Poorly controlled asthma may cause repeated emergency visits, hospital admissions, missed school days, reduced work productivity, sleep disturbance, limitation of physical activity, psychological distress, and reduced quality of life.

Severe asthma attacks can become life-threatening. Although asthma-related deaths are preventable in many circumstances, mortality continues to occur because of delayed recognition, inadequate access to appropriate medication, poor adherence, inappropriate treatment, severe disease, and delayed emergency care. WHO reports that asthma is often underdiagnosed and undertreated, particularly in low- and middle-income countries.

The economic burden extends beyond the cost of medication. Patients with uncontrolled asthma may require repeated consultations, investigations, emergency treatment, hospitalization, and time away from employment or education. Families may also experience financial stress when a child requires frequent medical care.

Classification of Asthma

Asthma can be classified in several ways. Classification based solely on symptom frequency is increasingly less useful than an approach that assesses symptom control, future risk, treatment requirements, and underlying characteristics.

Classification According to Clinical Pattern

Asthma may present with different clinical patterns, including:

• Allergic asthma
• Non-allergic asthma
• Adult-onset asthma
• Asthma with persistent airflow limitation
• Asthma associated with obesity
• Exercise-related asthma
• Occupational asthma
• Cough-variant asthma
• Asthma associated with aspirin or other nonsteroidal anti-inflammatory drug sensitivity
• Severe asthma
• Difficult-to-treat asthma

These categories can overlap. For example, a patient may have allergic asthma together with exercise-induced symptoms and obesity.

Allergic Asthma

Allergic asthma is commonly associated with other atopic conditions such as allergic rhinitis, eczema, or food allergy. Symptoms may be triggered by allergens such as house-dust mites, pollens, molds, animal allergens, or occupational substances.

Patients may have increased levels of immunoglobulin E and evidence of type 2 airway inflammation, although these findings are not present in every patient with asthma.

Non-Allergic Asthma

Some patients have asthma without obvious allergic sensitization. Their symptoms may be triggered by viral infections, irritants, exercise, cold air, occupational exposures, medications, or other factors.

Non-allergic asthma can be clinically difficult to distinguish from other airway disorders, making careful history-taking and objective assessment particularly important.

Occupational Asthma

Occupational asthma develops as a consequence of workplace exposure to sensitizers or irritants. Examples include exposure to flour dust, animal proteins, chemicals, paints, laboratory materials, cleaning agents, wood dust, and certain industrial substances.

Symptoms may improve during weekends, holidays, or periods away from work and worsen after returning to the workplace. Recognizing occupational asthma is important because continued exposure can lead to persistent disease and significant occupational consequences.

Causes and Risk Factors

Asthma does not usually have a single identifiable cause. Instead, it develops through interaction between genetic susceptibility and environmental exposures.

A family history of asthma increases the likelihood of developing the disease. Atopic conditions such as eczema and allergic rhinitis are also strongly associated with asthma. Environmental factors can influence both disease development and symptom severity.

Important risk factors include:

• Family history of asthma or allergic disease
• Atopy
• Allergic rhinitis
• Eczema
• Exposure to tobacco smoke
• Indoor air pollution
• Outdoor air pollution
• House-dust mites
• Molds
• Animal allergens
• Pollens
• Occupational dusts and chemicals
• Respiratory viral infections
• Prematurity
• Low birth weight
• Childhood exposure to tobacco smoke
• Obesity
• Certain medications
• Occupational sensitizers
• Genetic susceptibility

Early-life environmental exposures are particularly important because the lungs and immune system are developing during childhood. Prematurity, low birth weight, tobacco smoke exposure, and air pollution have all been associated with increased risk of asthma.

Obesity is also associated with asthma. The relationship is complex because obesity can increase respiratory symptoms, alter lung mechanics, and contribute to airway inflammation. Weight reduction in appropriate patients may improve asthma control.

Common Asthma Triggers

A trigger is a factor that can provoke or worsen asthma symptoms. Triggers vary considerably between patients.

Allergens

Common allergens include:

• House-dust mites
• Pollen
• Molds
• Animal dander and other animal allergens
• Cockroach allergens
• Certain occupational allergens

Not every patient with asthma has allergic triggers, and indiscriminate avoidance of suspected allergens without evidence of sensitization may not be beneficial.

Respiratory Infections

Viral respiratory infections are among the most common causes of asthma exacerbations, particularly in children. Viral infections can increase airway inflammation and hyperresponsiveness, leading to coughing, wheezing, and worsening breathlessness.

Exercise

Physical activity can provoke symptoms in some patients. Exercise-induced bronchoconstriction occurs because increased ventilation during exercise can alter airway temperature and water content, contributing to airway narrowing.

Importantly, exercise should not generally be avoided by people with asthma. With appropriate asthma control and preventive treatment when indicated, most patients can participate safely in physical activity and sports.

Cold Air

Cold, dry air can trigger bronchoconstriction in susceptible individuals. This may be particularly noticeable during outdoor exercise in cold weather.

Smoke and Air Pollution

Tobacco smoke, biomass fuel smoke, traffic-related air pollution, industrial emissions, and other airborne irritants can worsen asthma. WHO identifies tobacco smoke and indoor and outdoor air pollution among important environmental factors associated with asthma.

Strong Odors and Irritants

Perfumes, cleaning products, chemical fumes, aerosols, and other strong odors may provoke symptoms in some individuals. These exposures may act as irritants rather than true allergens.

Medications

Certain medications can worsen asthma in susceptible individuals. Aspirin and other NSAIDs can trigger respiratory symptoms in patients with NSAID-exacerbated respiratory disease. Some patients may also experience bronchospasm with beta-blockers.

Medication-related asthma symptoms should be assessed carefully because the relationship varies between individuals.

Pathophysiology of Asthma

The pathophysiology of asthma involves several interacting processes rather than a single abnormality. The major components include airway inflammation, bronchial hyperresponsiveness, reversible bronchoconstriction, mucus hypersecretion, airway edema, and structural remodeling.

Airway Inflammation

Inflammation is a central feature of asthma. Inflammatory cells and mediators contribute to swelling of the airway wall, increased mucus production, bronchial hyperresponsiveness, and airway narrowing.

The inflammatory pattern varies among patients. Type 2 inflammation involving cytokines such as interleukin-4, interleukin-5, and interleukin-13 is particularly important in many patients, especially those with allergic or eosinophilic asthma.

Other inflammatory pathways can also contribute, particularly in patients whose disease does not demonstrate prominent type 2 inflammation.

Bronchoconstriction

Bronchoconstriction occurs when airway smooth muscle contracts, reducing the diameter of the bronchial lumen. This increases resistance to airflow.

Because airway resistance rises markedly as airway diameter decreases, relatively small reductions in airway caliber can produce substantial increases in the work of breathing.

Bronchoconstriction is one reason why patients may experience rapid improvement after appropriate bronchodilator therapy.

Airway Edema

Inflammatory changes increase vascular permeability and cause swelling of the airway wall. This further narrows the lumen and contributes to airflow obstruction.

Mucus Hypersecretion

Asthma may increase mucus production and alter mucus properties. Thick mucus can obstruct smaller airways and contribute to ventilation abnormalities.

During a severe exacerbation, mucus plugging may become an important component of airflow limitation.

Airway Hyperresponsiveness

Airway hyperresponsiveness means that the airways constrict excessively in response to stimuli that would produce little or no bronchoconstriction in healthy individuals.

This abnormal responsiveness contributes to the variability of symptoms and airflow limitation characteristic of asthma.

Airway Remodeling

Long-standing airway inflammation may produce structural changes known collectively as airway remodeling. These may include thickening of the airway wall, increased smooth-muscle mass, subepithelial fibrosis, altered mucus glands, and other changes.

Airway remodeling can contribute to persistent airflow limitation in some patients.

Immunological Mechanisms

In allergic asthma, an allergen may activate antigen-presenting cells and promote a type 2 immune response. T-helper-2-associated cytokines contribute to eosinophilic inflammation, mucus production, IgE production, and airway hyperresponsiveness.

Interleukin-4 and interleukin-13 contribute to IgE-related responses and mucus-associated changes, while interleukin-5 plays an important role in eosinophil development and survival.

Mast cells can release mediators such as histamine, leukotrienes, and prostaglandins that contribute to bronchoconstriction and airway inflammation.

Eosinophils can release inflammatory proteins and mediators that damage airway epithelium and promote further inflammation.

However, asthma cannot be reduced to an allergic IgE-mediated mechanism. Several inflammatory phenotypes exist, and some patients have little evidence of classic type 2 inflammation.

Clinical Features of Asthma

The clinical presentation of asthma is highly variable. The most characteristic symptoms are:

• Wheezing
• Shortness of breath
• Chest tightness
• Cough

The symptoms often vary over time and may be triggered by specific exposures or circumstances.

Wheezing

Wheezing is a high-pitched musical sound produced by airflow through narrowed airways. It is commonly more prominent during expiration.

However, absence of wheezing does not exclude asthma. During very severe airflow obstruction, airflow may become so limited that little sound is produced. This can be a dangerous finding in a severely breathless patient.

Shortness of Breath

Patients may describe breathlessness as difficulty getting enough air, inability to take a deep breath, or a feeling of suffocation.

The severity can range from mild limitation during exercise to severe breathlessness at rest.

Chest Tightness

Some patients describe a pressure, tightness, or constricting sensation across the chest. This symptom may be particularly prominent in patients who do not experience obvious wheezing.

Cough

Cough may be the dominant or even the only symptom in some patients. Asthma should therefore be considered in patients with recurrent unexplained cough, particularly when symptoms worsen at night, with exercise, or after exposure to specific triggers.

Pattern of Asthma Symptoms

Asthma symptoms often show characteristic variability.

Patients may experience symptoms:

• At night
• In the early morning
• During exercise
• After exposure to allergens
• During respiratory infections
• During cold weather
• After exposure to smoke
• At work
• During particular seasons

A patient may have normal respiratory function between episodes, particularly in mild disease. This variability can make asthma difficult to diagnose if testing is performed when the patient is asymptomatic.

Physical Examination

Physical examination may be completely normal when asthma is well controlled.

During symptomatic periods, examination may reveal:

• Expiratory wheeze
• Prolonged expiration
• Tachypnea
• Increased work of breathing
• Use of accessory respiratory muscles
• Reduced air entry in severe obstruction
• Tachycardia
• Hyperinflation in some patients

In an acute severe attack, patients may appear anxious, unable to speak comfortably, or visibly exhausted.

A silent chest in a severely breathless patient is a potentially dangerous sign because very little air may be moving through severely narrowed airways.

Diagnosis of Asthma

The diagnosis of asthma requires clinical assessment supported, whenever possible, by objective evidence of variable expiratory airflow limitation.

GINA emphasizes that asthma should not be diagnosed only from symptoms because cough, wheeze, breathlessness, and chest tightness can occur in many other diseases. Objective testing can reduce misdiagnosis and inappropriate treatment.

Diagnosis generally involves:

1. A characteristic history of variable respiratory symptoms.
2. Assessment for alternative diagnoses.
3. Objective demonstration of variable expiratory airflow limitation when possible.

Spirometry

Spirometry is one of the most important investigations in asthma.

Important measurements include:

• Forced vital capacity (FVC)
• Forced expiratory volume in one second (FEV₁)
• FEV₁/FVC ratio

Asthma typically produces an obstructive ventilatory pattern when airflow limitation is present.

A key feature is variability in expiratory airflow. Demonstration of significant improvement in airflow after bronchodilator administration can support the diagnosis, although the absence of immediate reversibility does not exclude asthma.

Testing may need to be repeated if the initial spirometry result is normal but the clinical suspicion remains high. GINA's diagnostic framework includes spirometry and other objective approaches to demonstrate variable airflow limitation.

Peak Expiratory Flow

Peak expiratory flow, or PEF, measures the maximum speed at which a person can force air out of the lungs.

PEF monitoring can be useful when spirometry is unavailable or when symptoms and objective testing need to be compared over time.

Patients may record PEF measurements in the morning and evening for a period of time. Significant variability can support the presence of variable airflow limitation.

PEF is also useful for some patients as part of an individualized asthma action plan.

Bronchodilator Reversibility Testing

In bronchodilator testing, lung function is measured before and after administration of a bronchodilator.

An increase in expiratory airflow can provide objective evidence of variable airflow limitation. However, asthma is a variable disease, so reversibility may not always be demonstrated during a particular test.

Therefore, a negative bronchodilator test does not automatically exclude asthma.

Bronchial Provocation Testing

When symptoms strongly suggest asthma but routine spirometry is normal and there is no clear evidence of variable airflow limitation, bronchial provocation testing may be considered in appropriate settings.

Agents such as methacholine can be used to assess airway hyperresponsiveness. Exercise or other standardized challenges may also be used.

These tests should be performed under appropriate medical supervision because they intentionally provoke airway narrowing.

Fractional Exhaled Nitric Oxide

Fractional exhaled nitric oxide, or FeNO, can provide information about type 2 airway inflammation.

Elevated FeNO may support the presence of type 2 airway inflammation, particularly in patients with allergic or eosinophilic asthma. However, FeNO should not be interpreted as a standalone diagnostic test.

FeNO levels can be influenced by factors such as allergic disease, corticosteroid treatment, smoking, age, and other conditions.

Blood Eosinophils

Blood eosinophil count can provide information about the inflammatory phenotype of asthma.

Eosinophilia may support the presence of type 2 inflammation and can be useful when assessing difficult-to-treat or severe asthma and when considering targeted biologic therapies.

However, eosinophil levels fluctuate and must be interpreted in the clinical context.

Allergy Testing

Allergy evaluation may be useful in patients with suspected allergic asthma.

Possible investigations include:

• Skin-prick testing
• Serum-specific IgE testing

The purpose is not merely to label the patient as “allergic,” but to identify clinically relevant sensitization that may help explain symptoms and guide environmental management.

Chest Radiography

A chest X-ray is not routinely required to diagnose uncomplicated asthma.

It may be performed when an alternative diagnosis is suspected, when symptoms are atypical, or when there are features suggesting complications or another pulmonary disorder.

Chest imaging can help exclude conditions such as pneumonia, pneumothorax, foreign-body aspiration, cardiac disease, or other structural abnormalities in selected cases.

Differential Diagnosis

Several diseases can mimic asthma.

Important differential diagnoses include:

• Chronic obstructive pulmonary disease
• Vocal cord dysfunction or inducible laryngeal obstruction
• Bronchiectasis
• Heart failure
• Pneumonia
• Pulmonary embolism
• Gastroesophageal reflux disease
• Upper-airway cough syndrome
• Foreign-body aspiration
• Hyperventilation and dysfunctional breathing
• Interstitial lung disease
• Central airway obstruction
• Anxiety-related respiratory symptoms

Age, symptom pattern, smoking history, occupational exposure, examination findings, and objective testing help distinguish asthma from alternative diagnoses.

Asthma in Children

Asthma is particularly common in childhood. Children may present with recurrent wheezing, coughing, breathlessness, exercise limitation, or symptoms associated with viral infections.

Diagnosis can be challenging because young children may be unable to perform reliable lung-function tests.

A history of recurrent symptoms, family history of atopy, response to treatment, and careful assessment of alternative causes can assist diagnosis.

In children, viral infections are particularly important triggers. Exercise, allergens, smoke exposure, and environmental pollution can also worsen symptoms.

Treatment must take into account age, ability to use inhaler devices, caregiver understanding, adherence, and the child's developmental stage.

Asthma in Adolescents

Adolescents face unique challenges, including poor adherence, embarrassment about inhaler use, smoking or vaping exposure, changing routines, sports participation, and increasing independence from caregivers.

Asthma education should therefore include direct involvement of the adolescent rather than relying entirely on parents.

Adolescents should understand that controller treatment is intended to reduce airway inflammation and future risk, whereas reliever medication is used for symptom relief according to the prescribed regimen.

Adult-Onset Asthma

Asthma can begin during adulthood even when there was no childhood history of respiratory disease.

Adult-onset asthma may be associated with occupational exposures, obesity, allergic disease, respiratory infections, hormonal changes, or other factors.

Some patients with adult-onset asthma may have less obvious allergic features and may require careful evaluation to establish the diagnosis.

Occupational asthma should always be considered when symptoms began or worsened after starting a particular job.

Occupational Asthma

Occupational asthma is an important but sometimes overlooked form of asthma.

The history should include:

• Current occupation
• Previous occupations
• Workplace chemicals
• Dust exposure
• Fumes
• Animal proteins
• Flour or grain dust
• Latex
• Cleaning products
• Laboratory materials
• Workplace ventilation
• Symptom pattern during working and non-working periods

A characteristic pattern in which symptoms worsen at work and improve during holidays or weekends should raise suspicion.

Early recognition is important because continued exposure may worsen disease and potentially lead to persistent respiratory impairment.

Asthma Control

Asthma control has two major dimensions: current symptom control and future risk.

A patient may have few daily symptoms but still have significant risk of a severe exacerbation. Conversely, a patient may have frequent symptoms without necessarily having all the same risk factors for future severe events.

Assessment should therefore consider:

• Daytime symptoms
• Night waking
• Need for reliever medication
• Activity limitation
• Lung function
• Previous exacerbations
• Medication adherence
• Inhaler technique
• Exposure to triggers
• Comorbidities
• Smoking or vaping exposure
• Treatment intensity

GINA emphasizes control-based, personalized asthma management rather than relying on a single classification label.

Asthma Severity

Asthma severity is generally understood in relation to the amount of treatment required to achieve good control.

A patient requiring only low-intensity treatment to maintain control has a different disease burden from a patient who requires high-intensity treatment despite good adherence and correct inhaler technique.

It is important not to confuse uncontrolled asthma with severe asthma.

Poor adherence, incorrect inhaler technique, ongoing exposure to triggers, untreated rhinitis, obesity, smoking, and other factors can make asthma appear severe when the underlying disease may respond to appropriate correction of these problems.

Asthma Exacerbation

An asthma exacerbation is an acute or subacute worsening of symptoms and lung function compared with the patient's usual condition.

Common triggers include:

• Viral respiratory infections
• Allergen exposure
• Air pollution
• Tobacco smoke
• Occupational exposures
• Poor adherence to anti-inflammatory treatment
• Incorrect inhaler technique
• Interruption of controller medication

Exacerbations range from mild episodes that can be managed at home according to an individualized action plan to life-threatening attacks requiring emergency care.

Clinical Features of an Acute Severe Attack

Features suggesting a severe exacerbation can include:

• Marked breathlessness
• Difficulty speaking
• Rapid breathing
• Increased work of breathing
• Use of accessory muscles
• Tachycardia
• Reduced oxygen saturation
• Markedly reduced peak expiratory flow
• Poor response to initial reliever treatment
• Agitation or exhaustion

A patient who becomes drowsy, confused, exhausted, cyanosed, or develops a silent chest requires urgent emergency management.

Management Principles

The major goals of asthma treatment are to achieve and maintain good symptom control, prevent exacerbations, preserve lung function and activity levels, minimize treatment-related adverse effects, and reduce asthma-related mortality.

Management should be individualized according to age, symptom pattern, exacerbation risk, lung function, comorbidities, inhaler technique, adherence, patient preferences, and access to medication.

Current GINA guidance emphasizes the importance of inhaled corticosteroid-containing treatment rather than relying on short-acting bronchodilator therapy alone.

Non-Pharmacological Management

Medication is central to asthma treatment, but non-pharmacological measures are also important.

Trigger Management

Patients should identify clinically relevant triggers and reduce exposure when feasible.

For example, a patient with occupational asthma may require workplace assessment and exposure reduction. A patient with allergic asthma may benefit from targeted allergen management when a clinically relevant allergen has been identified.

Avoiding unnecessary restrictions is equally important. Patients should not be advised to eliminate foods, pets, or environmental exposures without a reasonable clinical basis.

Smoking Cessation

Smoking can worsen respiratory symptoms and reduce treatment response. Patients who smoke should be offered evidence-based smoking cessation support.

Second-hand smoke exposure should also be minimized.

Physical Activity

Regular physical activity is generally encouraged. Good asthma control should allow most patients to participate in exercise.

Patients who experience exercise-induced bronchoconstriction should have their overall asthma control assessed and may require preventive treatment according to their individualized regimen.

Weight Management

For patients with overweight or obesity, appropriate weight management may improve respiratory symptoms and asthma control.

Weight reduction should be approached as part of overall health management rather than as a replacement for asthma medication.

Asthma Medications

Asthma medications can broadly be divided into anti-inflammatory controller treatments, reliever medications, and add-on therapies.

Inhaled Corticosteroids

Inhaled corticosteroids, or ICS, are fundamental anti-inflammatory medicines in asthma management.

Examples include:

• Beclometasone
• Budesonide
• Fluticasone
• Mometasone
• Ciclesonide

ICS reduce airway inflammation and substantially reduce the risk of severe exacerbations.

Their importance is one reason modern asthma management does not rely on bronchodilator-only treatment.

Bronchodilators

Bronchodilators relax airway smooth muscle and improve airflow.

Beta-2 agonists include:

• Salbutamol
• Terbutaline
• Formoterol

Long-acting bronchodilators are generally used as part of appropriate asthma regimens rather than as isolated treatment.

ICS-LABA Therapy

Combination inhalers contain an inhaled corticosteroid and a long-acting beta-2 agonist.

Examples include combinations containing:

• Budesonide/formoterol
• Beclometasone/formoterol
• Fluticasone/salmeterol
• Fluticasone/vilanterol

The choice depends on the patient's treatment plan, age, local availability, device, and guideline recommendations.

ICS-Formoterol

An important modern treatment approach uses an inhaled corticosteroid combined with formoterol as the reliever, with or without regular maintenance doses depending on the treatment track.

This approach allows the patient to receive anti-inflammatory corticosteroid treatment when using the reliever and is the preferred strategy in GINA's Track 1 for appropriate adults and adolescents.

Leukotriene Receptor Antagonists

Montelukast is a leukotriene receptor antagonist that can be used in selected patients.

It may be useful in some patients with asthma, particularly when allergic rhinitis or exercise-related symptoms coexist, but it is generally less effective than inhaled corticosteroid-containing therapy for preventing exacerbations.

Patients and caregivers should also be aware of regulatory warnings concerning possible neuropsychiatric adverse effects associated with montelukast.

Long-Acting Muscarinic Antagonists

Long-acting muscarinic antagonists such as tiotropium may be added in selected patients whose asthma remains uncontrolled despite appropriate inhaled therapy.

These medications reduce cholinergic bronchoconstriction and can provide additional bronchodilation.

Inhaler Technique

Correct inhaler technique is one of the most important practical aspects of asthma management.

A patient can be prescribed an appropriate medication but receive inadequate treatment if the medication is not delivered effectively to the lungs.

Common errors include:

• Incorrect inhaler preparation
• Poor coordination between inhalation and actuation
• Inhaling too rapidly or too slowly for the device
• Failure to inhale deeply when required
• Failure to hold the breath after inhalation when appropriate
• Not using a spacer with a pressurized metered-dose inhaler when indicated
• Failure to maintain the inhaler correctly

Healthcare professionals should regularly observe inhaler technique rather than simply asking patients whether they know how to use the device.

Spacer Devices

A spacer can improve medication delivery from a pressurized metered-dose inhaler and may make administration easier, especially for children.

WHO notes that spacers help aerosol medication reach the lungs more effectively and can be particularly useful when inhaler technique is difficult.

Adherence to Treatment

Poor adherence is a major reason for uncontrolled asthma.

Reasons for poor adherence may include:

• Forgetfulness
• Cost of medication
• Fear of corticosteroid adverse effects
• Lack of understanding of asthma
• Complex treatment schedules
• Inconvenient inhaler devices
• Perception that medication is unnecessary when symptoms disappear
• Cultural beliefs
• Lack of access to healthcare
• Poor communication with healthcare professionals

Patients should be asked about adherence in a nonjudgmental manner.

Simply telling a patient to “take the medication regularly” is often insufficient. Healthcare professionals should identify the specific barrier and address it.

Asthma Action Plan

Every patient with persistent asthma should ideally have a personalized written asthma action plan.

The plan should explain:

• The patient's usual treatment
• How to recognize worsening symptoms
• How to respond to worsening symptoms
• When to increase or use prescribed reliever treatment
• When to contact a healthcare professional
• When to seek emergency care

An action plan helps patients respond earlier to deterioration rather than waiting until severe respiratory distress develops.

Stepwise Treatment

Asthma treatment is commonly adjusted in a stepwise manner.

If asthma is not adequately controlled, treatment may need to be increased after checking:

• Diagnosis
• Adherence
• Inhaler technique
• Exposure to risk factors
• Comorbidities
• Treatment regimen

If asthma remains well controlled for an appropriate period, treatment may sometimes be stepped down to the lowest effective level.

The objective is not to use the maximum possible amount of medication. The goal is to maintain good control and minimize risk using the lowest effective treatment intensity.

Treatment of Acute Asthma Exacerbation

Acute exacerbations require rapid assessment of severity and prompt treatment.

Management commonly involves:

• Rapid-acting bronchodilator therapy
• Oxygen when clinically indicated
• Systemic corticosteroids for appropriate moderate or severe exacerbations
• Repeated assessment of response
• Identification of precipitating factors
• Escalation to emergency or hospital care when required

Severe attacks may require repeated or continuous bronchodilator treatment, systemic corticosteroids, oxygen, and additional emergency interventions under medical supervision.

Antibiotics are not routinely indicated for asthma exacerbations unless there is evidence of a bacterial infection or another specific indication.

Emergency Warning Signs

Patients and families should recognize signs requiring urgent medical attention.

These include:

• Severe difficulty breathing
• Inability to speak normally because of breathlessness
• Blue or gray discoloration of lips or skin
• Confusion
• Drowsiness
• Exhaustion
• Very poor response to prescribed reliever treatment
• Severe chest tightness
• Markedly reduced peak flow when a patient uses a personal action plan
• Silent chest in a severely breathless patient

Severe asthma attacks can be fatal, so delayed treatment should be avoided.

Severe and Difficult-to-Treat Asthma

Difficult-to-treat asthma refers to asthma that remains uncontrolled despite treatment or requires relatively intensive therapy.

Before labeling a patient as having severe asthma, healthcare professionals should systematically investigate potentially modifiable factors.

These include:

• Incorrect diagnosis
• Poor adherence
• Incorrect inhaler technique
• Continued allergen or irritant exposure
• Smoking
• Obesity
• Chronic rhinosinusitis
• Gastroesophageal reflux
• Obstructive sleep apnea
• Anxiety or dysfunctional breathing
• Medication interactions
• Occupational exposures

Severe asthma is a distinct category in which asthma remains uncontrolled despite optimized high-intensity treatment and management of contributory factors, or requires such treatment to maintain control. GINA provides dedicated guidance for difficult-to-treat and severe asthma.

Biologic Therapy

Biologic medications have transformed the management of selected patients with severe asthma.

They are generally considered after careful assessment of phenotype, adherence, inhaler technique, comorbidities, exacerbation history, lung function, and biomarkers.

Available biologic approaches may target pathways involving:

• IgE
• Interleukin-5
• Interleukin-5 receptor
• Interleukin-4 receptor alpha
• Thymic stromal lymphopoietin

Examples of biologic medicines include omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab.

These medications are not required by most patients with asthma. They are specialized treatments for selected patients with severe disease and should be initiated and monitored by clinicians experienced in severe asthma management.

Comorbidities Associated With Asthma

Comorbid conditions can worsen asthma symptoms and complicate management.

Important comorbidities include:

• Allergic rhinitis
• Chronic rhinosinusitis
• Nasal polyps
• Atopic dermatitis
• Obesity
• Gastroesophageal reflux disease
• Obstructive sleep apnea
• Anxiety
• Depression
• Vocal cord dysfunction or inducible laryngeal obstruction

Treating relevant comorbidities can improve overall respiratory health and may improve asthma control.

Asthma and Allergic Rhinitis

Asthma and allergic rhinitis frequently coexist because they share inflammatory pathways and risk factors.

Patients with asthma should be assessed for symptoms of rhinitis such as:

• Sneezing
• Nasal itching
• Nasal obstruction
• Watery nasal discharge
• Postnasal symptoms

Appropriate treatment of rhinitis can improve upper-airway symptoms and may contribute to better overall respiratory control.

Asthma and Obesity

Obesity can complicate asthma diagnosis because breathlessness and reduced exercise tolerance may result from obesity itself.

Obesity is also associated with increased asthma risk and can contribute to poorer symptom control.

Management should distinguish asthma-related symptoms from symptoms caused by reduced physical fitness, sleep apnea, cardiovascular disease, or obesity-related respiratory mechanics.

Asthma and Gastroesophageal Reflux

Gastroesophageal reflux disease may coexist with asthma.

Reflux can produce cough, throat symptoms, and respiratory discomfort that may be mistaken for uncontrolled asthma.

However, treating asymptomatic reflux solely to improve asthma control is not necessarily beneficial. Treatment should be based on appropriate clinical assessment.

Asthma and Pregnancy

Asthma can occur during pregnancy and should be appropriately controlled because uncontrolled asthma may pose risks to both the pregnant patient and fetus.

Treatment decisions should balance the risks of uncontrolled asthma against medication risks. In general, appropriate asthma therapy should not be stopped simply because a patient becomes pregnant.

Pregnant patients with asthma should have regular clinical monitoring and should seek medical advice before changing prescribed medication.

Asthma Prevention

Asthma cannot always be prevented because genetic and early-life factors contribute to susceptibility. However, exacerbations and poor control can often be reduced.

Important preventive strategies include:

• Avoiding tobacco smoke
• Reducing relevant occupational exposures
• Improving adherence to controller therapy
• Correcting inhaler technique
• Following an asthma action plan
• Managing allergic disease
• Maintaining appropriate physical activity
• Managing obesity when relevant
• Receiving recommended vaccinations
• Monitoring symptoms and lung function when appropriate
• Recognizing early signs of worsening disease

WHO emphasizes that appropriate inhaled medication can control symptoms and allow people with asthma to lead normal, active lives.

Vaccination and Respiratory Health

Respiratory infections can trigger asthma exacerbations. Appropriate vaccination according to age, risk factors, and local public-health recommendations can therefore be an important component of preventive healthcare.

Influenza vaccination may be particularly relevant for individuals at increased risk of complications from influenza.

Other vaccinations should be provided according to national recommendations and individual medical circumstances.

Patient Education

Asthma education should be an ongoing process rather than a single conversation.

Patients should understand:

• What asthma is
• Why airway inflammation matters
• What triggers their symptoms
• Which medication controls inflammation
• Which medication provides symptom relief
• How to use their inhaler
• How to recognize worsening symptoms
• When to seek medical help
• How to use their written action plan

Education improves the patient's ability to participate actively in disease management.

Prognosis

The prognosis of asthma varies widely.

Many patients achieve excellent control and can live normal, active lives. Others experience recurrent exacerbations, persistent symptoms, or progressive airflow limitation.

Poor prognosis is associated with factors such as frequent severe exacerbations, smoking exposure, persistent uncontrolled symptoms, poor adherence, inadequate access to treatment, and certain severe inflammatory phenotypes.

Early diagnosis, appropriate anti-inflammatory treatment, avoidance of relevant triggers, regular monitoring, and patient education can substantially improve outcomes.

Complications of Asthma

Poorly controlled asthma can lead to several complications.

These include:

• Recurrent acute exacerbations
• Emergency department visits
• Hospitalization
• Sleep disturbance
• Reduced exercise capacity
• Missed school or work
• Reduced quality of life
• Psychological distress
• Persistent airflow limitation
• Medication-related adverse effects
• Respiratory failure during life-threatening exacerbations
• Death

Severe exacerbations are particularly dangerous and require rapid recognition and treatment.

Common Myths About Asthma

Asthma Is Only a Childhood Disease

Asthma can begin at any age. Some patients develop symptoms during adulthood despite having no childhood history of asthma.

People With Asthma Should Avoid Exercise

This is incorrect. With appropriate management, most people with asthma can exercise and participate in sports.

Asthma Is Always Caused by Allergy

Allergic asthma is common, but not all asthma is allergic. Several inflammatory and clinical phenotypes exist.

Inhaled Corticosteroids Are the Same as Anabolic Steroids

Inhaled corticosteroids are anti-inflammatory medicines used in very small doses directly in the airways. They are pharmacologically different from anabolic steroids used for muscle growth.

A Reliever Inhaler Alone Is Enough

Relying solely on short-acting bronchodilator treatment does not address the underlying airway inflammation and may leave patients at risk of severe exacerbations. Modern asthma strategies emphasize ICS-containing treatment.

Asthma Medication Can Be Stopped Whenever Symptoms Improve

Symptoms may disappear while underlying airway inflammation or future risk remains. Treatment changes should be made according to an individualized management plan rather than stopping medication abruptly without medical guidance.

Role of Healthcare Professionals

Effective asthma management requires collaboration between patients and healthcare professionals.

Physicians assess diagnosis, severity, comorbidities, and treatment requirements. Nurses and pharmacists play major roles in education, inhaler technique, adherence assessment, monitoring, and patient counseling.

Pharmacists can identify medication-related problems, check inhaler technique, explain dosing schedules, and reinforce adherence.

A multidisciplinary approach can be especially valuable for patients with severe or difficult-to-treat asthma.

Long-Term Monitoring

Asthma is a chronic condition requiring periodic reassessment.

Follow-up should evaluate:

• Symptom control
• Exacerbations
• Lung function
• Medication adherence
• Inhaler technique
• Trigger exposure
• Comorbidities
• Adverse effects
• Patient concerns
• Treatment goals

Treatment should be adjusted when the patient's clinical situation changes.

The ultimate goal is sustained control with the minimum treatment intensity necessary to maintain good control and reduce future risk.

Role of Spirometry in Follow-Up

Spirometry can help assess lung function over time.

A reduction in lung function may indicate worsening disease, poor control, an alternative diagnosis, or persistent airflow limitation.

Repeated measurements can also help evaluate the response to treatment and provide objective information when symptoms are difficult to interpret.

Importance of Personalized Asthma Care

Asthma management should not follow a rigid one-size-fits-all model.

Two patients with similar symptoms may have different triggers, inflammatory phenotypes, comorbidities, adherence barriers, and treatment responses.

Personalized care therefore considers:

• Patient age
• Symptom pattern
• Exacerbation history
• Lung function
• Allergic status
• Biomarkers when appropriate
• Occupational exposures
• Comorbidities
• Medication access
• Inhaler preference and ability
• Patient goals
• Treatment response

This individualized approach is consistent with the modern control-based strategy emphasized by GINA.

Key Points for Medical Students

Asthma should be remembered as a heterogeneous chronic inflammatory airway disease characterized by variable respiratory symptoms and variable expiratory airflow limitation.

The four classic symptoms are:

• Wheeze
• Breathlessness
• Chest tightness
• Cough

The symptoms commonly vary over time and may worsen at night, during exercise, or after exposure to specific triggers.

The fundamental pathophysiological abnormalities include:

• Airway inflammation
• Bronchial hyperresponsiveness
• Bronchoconstriction
• Airway edema
• Mucus hypersecretion
• Airway remodeling in some patients

Diagnosis should ideally be supported by objective evidence of variable expiratory airflow limitation, commonly through spirometry and bronchodilator responsiveness testing.

Treatment should address both symptoms and the underlying inflammatory disease. Inhaled corticosteroid-containing therapy is central to modern asthma management, while bronchodilators provide relief of bronchoconstriction.

Before escalating treatment for uncontrolled asthma, always reassess the diagnosis, adherence, inhaler technique, trigger exposure, smoking, and comorbidities.

Severe asthma should not be diagnosed simply because a patient has frequent symptoms. True severe asthma requires careful assessment and optimized management, often with specialist input.

Most importantly, asthma is a manageable chronic disease. Appropriate diagnosis, anti-inflammatory treatment, education, trigger management, monitoring, and timely treatment of exacerbations can dramatically reduce morbidity and allow patients to maintain normal daily activities.